Johnson + Johnson's TECNIS Eyhance Toric II IOL launches in Europe

Article

According to the company, more than 400 eyes of patients from 12 European countries have been fitted with the TECNIS Eyhance Toric II IOL, with surgeons surveyed noting that their patients are pleased with the results.

Johnson + Johnson's TECNIS Eyhance Toric II IOL launches in Europe

Johnson + Johnson Vision announced today it is kicking off the availability of its TECNIS Eyhance Toric II IOL with TECNIS Simplicity Delivery System for the treatment of cataracts patients with astigmatism in Europe.

According to the company, the monofocal lens allows for high-quality vision at both intermediate and far distances1 and is specifically engineered for rotational stability.1 The lens allows patients to achieve significantly improved intermediate vision, compared with a standard aspheric monofocal IOL, along with 20/20 distance vision.1

According to Filomena Ribeiro, MD, PhD, FEBO, head director of ophthalmology at Hospital da Luz in Lisbon, Portugal, the haptic design and rotational stability of the TECNIS Eyhance Toric II IOL, has allowed her to offer her patients immediate improvements in their functional vision, while also correcting their astigmatism.

“Having implanted the TECNIS EyhanceToric II IOL, I can confidently say that this IOL is a game-changer in the monofocal category and in helping my patients get back to spending more time doing what they love,” she said in a statement.

Related: Posterior corneal elevation: Is there a role for premium IOLs?

A survey of 17 leading European ophthalmologists found that their patients were satisfied with the lens.2 Meanwhile, more than 79% perceived their patients as being very satisfied with their intermediate and distance vision.2

Additionally, 94% of those surveyed were very satisfied with the handling while implanting the lens, while nearly two thirds rated the overall performance of the lens as excellent compared to other toric IOLs.2 More than 80% also rated the rotational stability of the lens as excellent compared to other toric IOLs. All those surveyed said they were very likely to continue to use the lens in the future.2

Related: Ray tracing and IOL modelling in AMD patients

Erin McEachren, regional vice president, EMEA, Johnson + Johnson Surgical Vision, said the rollout offers the benefits of its most advanced monofocal IOL to cataract patients with astigmatism.

“It is an important first in Europe for the monofocal IOL category, as today most lenses in this category only correct vision to help patients with cataracts see things at a distance, and therefore do not improve the intermediate vision that is required for many important daily tasks,” McEachren said in a statement. “This is another breakthrough in meeting the ever-changing and evolving needs of our patients across Europe and the world.”

References
DOF2018CT4015 – Clinical evaluation of the TECNIS Eyhance Model ICB00 – 6-month clinical study. Sep 2018. Based on a clinical study, N=134 achieved mean 20/20 monocular pooled distance BCDVA.
TECNIS Eyhance Toric II IOL – Survey of 17 surgeons about experiences with DIU. May 2021. REF2021CT4156.

Related Content: Cornea | Cataract & Refractive | Retina

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.